Gammaherpesviruses such as Epstein-Barr virus (EBV, human herpesvirus 4) and Kaposi sarcoma-associated herpesvirus (KSHV, human herpesvirus 8) establish lifelong infection in the host. To further this lifestyle, they encode homologs of cellular cytokines and cytokine receptors with the overarching goal to escape from or to blunt host antiviral defenses. EBV encodes mimics of human interleukin (hIL)-10 and a G protein-coupled receptor protein with sequence similarity to CXCR, whereas KSHV encodes homologs of hIL-6, 3 CC chemokine ligands, and a G protein-coupled receptor with sequence similarity to IL8 receptor alpha. This review focuses on the EBV IL-10 homolog and the KSHV IL-6 homolog with respect to virus biology and pathogenesis of the virus-associated diseases.

**Introduction**

The host keeps guard against pathogens by deploying innate and adaptive immune responses. The innate immune system defends the host by impeding viral replication and activating the adaptive antiviral responses, and the adaptive immune response provides the host with the ability to neutralize virus particles and to remember a specific virus attack. For successful replication and transmission, viruses must subvert, blunt, or escape host antiviral activities. To accomplish this goal, viruses evolved immune evasion strategies, which include viral mimics of host cytokines and/or cytokines receptors. These strategies are essential for viruses that establish a lifelong presence in the host. This is termed persistent infection if there is consistent evidence of circulating virus or viral shedding of the same strain in the absence of reinfection, and latent infection if the virus can only be intermittently detected in blood, lymph, or body secretions.

Gammaherpesvirus infections are prime examples of latent pathogen infections. The human gammaherpesviruses include Epstein-Barr virus (EBV, also known as human herpesvirus 4) and Kaposi sarcoma-associated herpesvirus (KSHV, or human herpesvirus 8). These are linked to human cancers of the immune compartment. EBV is associated with the development of endemic Burkitt’s lymphoma, classic Hodgkin lymphoma, lymphoepithelioma-like nasopharyngeal carcinoma, and a certain subtype of gastric adenocarcinoma (IARC 2010). KSHV is associated with Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and the plasmablastic variant of multicentric Castleman disease (MCD) and in some instances diffuse large B-cell lymphoma (Carbone and others 2009). Both viruses have a large double-stranded DNA genome (~172 kb for EBV and ~145 kb for KSHV) and encode over 80 open reading frames (ORFs). Many of the proteins, which are encoded by these ORFs, are highly immunogenic, particularly if present in the virions. Virions are produced during the lytic (productive) cycle, whereas only a very limited set of proteins is translated during the latent infection phase.

EBV encodes 3 host cytokine or chemokine receptor mimics. They are an interleukin (IL)-10 homolog encoded by BamHI-C fragment rightward reading frame 1 (BCRF1) (Moore and others 1990), a CXCR homolog encoded by BILF1 (Paulsen and others 2005), and EBV-induced gene 3 (EBI3), an IL-12p40-related protein, which forms heterodimeric IL-27 with p28 (IL-30), which is itself an IL-12p35-related polypeptide (Pflanz and others 2002).

KSHV encodes an IL-6 homolog (Moore and others 1996; Neipel and others 1997; Nicholas and others 1997), an IL-8 receptor alpha homolog (ORF74) (Cesarman and others 1996; Bais and others 1998), and 3 CC-chemokine ligands (Moore and others 1996; Boshoff and others 1997; Sozzani and others 1998; Dairaghi and others 1999; Stine and others 2000). Other immune evasion strategies by gammaherpesviruses have been reviewed elsewhere (Stevenson 2004; Nicholas 2005; Coscoy 2007; Liang and others 2008; Blake 2010; Lee and others 2010; Rowe and Zuo 2010). In this review, we focus on roles of viral IL (vIL)-6 and vIL-10 with respect to the pathobiology of gammaherpesviruses.

**EBV IL-10 Homolog**

IL-10 was originally reported as cytokine synthesis inhibitory factor (CSIF) produced by T helper 2 (Th2) cells, which inhibited Th1-derived gamma interferon (IFN-γ)
production (Fiorentino and others 1989). It is now known that IL-10 is not just \( \text{T}_{12} \)-specific, but expressed by many different kinds of immune cells including \( \text{T}_{12} \), \( \text{T}_{17} \), \( \text{Reg} \), B cells, macrophages, and myeloid dendritic cells, indicating its role in controlling diverse immune responses. In addition to IFN-\( \gamma \), IL-10 inhibits the expression of IL-1\( \alpha \), IL-1\( \beta \), IL-6, IL-12, IL-18, granulocyte/macrophage colony stimulating factor, tissue necrosis factor, and others. Human IL-10 (hIL-10) has immunosuppressive properties as well as immunostimulatory properties. On the one hand, it functions to deactivate macrophages (Bogdan and others 1991) and it inhibits antigen-specific T-cell proliferation by interfering with the monocytes' antigen-presenting capacity via down-regulation of class II major histocompatibility complex (MHC II) expression (de Waal Malefyt and others 1991). On the other hand, hIL-10 cooperates with transforming growth factor \( \beta \) to stimulate anti-CD40-activated naive human B cells to secret immunoglobulin A (Defrance and others 1992).

The EBV BCRF1 gene product (vIL-10) shares 70% and 80% amino acid sequence identity with mouse and hIL-10/CSIF, respectively (Moore and others 1990; Vieira and others 1991). The vIL-10 promoter is highly methylated and inactive in latently infected B cells (Niller and others 2001) and the vIL-10 protein is expressed late during the lytic cycle (Hudson and others 1985). Yet, the vIL-10 is expressed also within the first 6–9 h after infection of human B cells (Miyazaki and others 1993; Touitou and others 1996). This divergent regulation represents a common strategy of both the KSHV and the EBV IL homologs. Even though the vILs as well as the viral chemokine receptor homologs are typically classified as “lytic” cycle viral genes, they are also transcribed in response to specific host cell signaling events outside the rigid framework of the canonical transcriptional cascade that governs herpesvirus lytic replication (Chatterjee and others 2002). Thus, one might speculate that they have a purpose in latent persistence in addition to their role in support of viral replication and progeny production.

The EBV vIL-10 inhibits IFN-\( \gamma \) synthesis by T-cell-dependent antigen-stimulated mouse Th1 cells and phytohemagglutinin-activated human peripheral blood mononuclear cells (PBMCs) analogous to hIL-10 (Hsu and others 1990; Moore and others 1990). The inhibition of IFN-\( \gamma \) from IL-2-activated PBMCs suggests that the vIL-10 may also act on natural killer cells (NK), which are the major source of IL-2 in these assays (Hsu and others 1990). NK and cytotoxic T-cell (CTL) activity was reduced in mice infected with a recombinant vaccinia virus expressing the vIL-10 (Kurilla and others 1993). The EBV vIL-10 cooperates with hIL-10 to downregulate the peptide transporter protein (TAP1), which in turn limits antigen presentation mediated by MHC I molecules. This may influence the CTL’s role in recognition of EBV-infected B cells (Zeidler and others 1997).

Both hIL-10 and vIL-10 enhance proliferation and differentiation of EBV-negative, normal, mature B cells, but vIL-10 does not upregulate MHC II expression (Go and others 1990; Rousset and others 1992). Human and mouse IL-10 stimulate the proliferation of mature and immature T cells, whereas their EBV counterpart does not (MacNeil and others 1990). This is probably due to its lower affinity for the IL-10 receptor \( \alpha \) (IL-10R\( \alpha \)). A related line of inquiry demonstrated that the EBV vIL-10 had 1,000-fold lower affinity for the IL-10R and this resulted in a much reduced ability to inhibit IL-2 secretion from CD4\( ^{+} \) T cells (Liu and others 1997). Thus emerges a picture wherein the EBV vIL-10 displays all the inhibitory phenotypes of hIL-10, but is severely impaired with regard to its pro-proliferative capabilities (Fig. 1).

A possible explanation for the lack of pro-proliferative activity toward T cells is a single amino acid change at position 87. An isoleucine is required at position 87 for hIL-10 immunostimulatory functions. When this residue was changed into alanine, the immunostimulatory activity of hIL-10 was destroyed (Ding and others 2000). The EBV vIL-10 has an alanine at the corresponding position in vIL-10. The crystal structure of vIL-10 reveals that two 17-kDa polypeptides form a homodimer-like hIL-10, but with subtle changes in conformation. The resulting orientation change of vIL-10 on a soluble IL-10R1 fragment (sIL-10R1) may cause the reduced affinity of vIL-10 for sIL-10R1 (Zdanov and others 1997; Yoon and others 2005).

The lack of immunostimulatory potency has prompted explorations of vIL-10 as a possible therapeutic for autoimmune diseases or chronic inflammation. In animal models, adenoviral-mediated transfer of vIL-10 was effective in inhibiting collagen-induced arthritis (Apparailly and others 1998; Lehrman and others 2005; Keravala and others 2006), ameliorating symptoms of autoimmune ocular diseases (De Kozak and others 2002; Verwaerde and others 2003; Zhu and others 2004), and suppressing autoimmune diabetes via inhibition of T\( \text{H}_2 \) cell activation (Kawamoto and others 2001; Yang and others 2002b). The EBV IL-10 homolog also reduced IL-1 levels in a particle-associated inflammation mouse air pouch model (Yang and others 2002a) and suppressed crescentic glomerulonephritis in a rat model (Higuchi and others 2003). Because of the lack of immunostimulatory functions, vIL-10 had advantages over hIL-10 in transplantation models including a rat kidney transplantation model, a mouse cardiac allograft model, and a mouse hematopoietic stem cell therapy (Qin and others 1996; Salgar and others 2004; Chen and others 2007).

How the EBV IL-10 homolog contributes to EBV-transformed B-cell proliferation remains to be determined. On the one hand, lymphoblastoid cell lines, which are infected with EBV recombinants devoid of vIL-10, show no difference in latent infection, virus replication, and tumorigenicity in SCID mice (Swaminathan and others 1993). On the other hand, oligonucleotides against vIL-10 mRNA inhibit aspects of EBV-dependent B-cell transformation (Miyazaki and others 1993), and the addition of exogenous vIL-10 enhances growth transformation of B cells by EBV (Stuart and others 1995) as well as the initial immortalization of EBV-infected B lymphocytes, which is dependent on vIL-10 (Irons and Le 2008).

**KSHV IL-6 Homolog**

IL-6 is a cytokine with pro- and anti-inflammatory functions. It was originally reported as a B-cell stimulating and differentiating factor secreted by T cells, which induces terminal maturation into plasma cells (Okada and others 1983; Hirano and others 1986; Muraguchi and others 1988). It is now known that IL-6 is not only secreted by T-cells, but also by a variety of other cells including macrophages, fibroblasts, synovial cells, endothelial cells, glial cells, and keratinocytes. IL-6 folds into a 4-helix bundle, which is the common motif for helical cytokines (Bazan 1990). The IL-6 family of cytokines comprises IL-11, oncostatin M, and
leukemia inhibitory factor in addition to IL-6. Cytokines of the IL-6 family act via receptor complexes containing a signal-transducing protein, gp130. hIL-6 binds to 2 domains of gp130 and a specific α subunit of IL-6R (IL-6Rα/gp80) to initiate intracellular signal transduction (Grotzinger and others 1997). Dysregulated expression of IL-6 is involved in inflammation and hematopoietic malignancies, such as cardiac myxoma, Castleman disease (CD), rheumatoid arthritis (RA), and systemic-onset juvenile idiopathic arthritis (SoJIA). Therapeutic approaches targeted against IL-6 and/or IL-6R complexes are in clinical testing (eg, humanized anti-IL6: Sirukumab, ALD518, and others). A humanized anti-IL-6R antibody, tocilizumab, has shown efficacy against immune-mediated inflammatory diseases such as RA, SoJIA, systemic lupus erythematosus, adult-onset Still disease, Takayasu arthritis, and systemic sclerosis as well as MCD (Murakami and Nishimoto 2011).

The KSHV IL-6 homolog (vIL-6) shows only 24.8% amino acid identity to hIL-6 (Moore and others 1996; Neipel and others 1997; Nicholas and others 1997). However, its crystal structure follows the canonical 4-helix bundle fold (Chow and others 2001; Boulanger and others 2003). The vIL-6 is an early lytic gene; however, the vIL-6 can also respond to cell signaling events directly and discordantly from other viral lytic genes, suggesting vIL-6’s roles in survival of KSHV-infected B cells (Chatterjee and others 2002; Chang and others 2005; Chandriani and Ganem 2010). In MCD, the vIL-6 is constitutively expressed in virally infected B cells and can thus be considered a latent gene in this population. Host IFN-α signaling is inhibited by vIL-6. However, IFN-α itself can activate vIL-6 through an IFN-stimulated response element in the vIL-6 promoter. Subsequently, the expression of vIL-6 acts in a negative feedback loop to block IFN-α antiviral signaling (Chatterjee and others 2002).

Analogous to its cellular counterpart, vIL-6 functions to transduce signals via gp130 (Molden and others 1997) and activates CCAAT/enhancer-binding protein transcription factors, Janus kinase/signal transducer and activator of transcription, and mitogen-activated protein kinase signaling pathways (Osborne and others 1999; Hideshima and others 2000).

The first important difference between hIL-6 and vIL-6 is that vIL-6 requires only gp130 for signaling. This is unlike hIL-6, which needs the high-affinity coreceptor IL-6R (gp80) in complex with gp130 (Molden and others 1997; Chow and others 2001). The crystal structure of the vIL-6 signaling complex shows the vIL-6 dimer forming a tetramer with gp130 (vIL-6α/gp130β) (Chow and others 2001). This led to advanced structural and functional studies (Li and others 2001; Li and Nicholas 2002; Boulanger and others 2004; Dela Cruz and others 2004, 2009; Chen and Nicholas 2006; Hu and Nicholas 2006). The replacement of hIL-6 with the corresponding residues of the gp130 contact site III and BC loop of vIL-6 confers gp80 independence to the hIL-6 (Adam and others 2009). Based on these observations, one can speculate that the conformational change between hIL-6 and vIL-6 is a key factor in determining the gp80-independent binding of the vIL-6 to gp130. In fact, vIL-6 may exist in multiple signaling complexes, a gp80-independent tetramer (vIL-6α/gp130β) and gp80-dependent hexamer (gp130β/gp80α/vIL-6α).

The second important difference between hIL-6 and vIL-6 is that most vIL-6 is retained in endoplasmic reticulum (ER), implying autocrine stimulation as the dominant mode of action (Chen and others 2009b, Fig. 1). An ER chaperone protein, calnexin, interacts with vIL-6 to mediate proper protein folding (Chen and others 2009a). This is in contrast to hIL-6, which is quickly secreted (Rose-John and others 1993).

These 2 biochemical differences translate into functional and biological differences. The vIL-6 stimulates intracellular signaling in human B cells, which are IL-6R (gp80) negative and respond poorly or not at all to hIL-6 (Breen and others 2001). In the presence of gp80, the vIL-6 can support growth of IL-6/IL-3-dependent gp80- /gp130- BAF-130 cells better than its human counterpart (Hu and Nicholas 2006).

The KSHV vIL-6 augments growth and survival of PEL cell lines (Jones and others 1999; Chatterjee and others 2002) and increases tumorigenicity in athymic nude mice (Aoki and others 1999). The vIL-6 is also important for PEL tumorigenesis, because it induces VEGF-1, a paracrine factor that has been implicated in the pathogenesis of PEL and KS (Aoki and others 1999; Aoki and Tosato 1999; Jones and others 1999). Thus, it contributes to the transforming potency of KSHV. Neutralizing antibodies against vIL-6, IL-6R, or gp130 reduced the growth of some PEL cell lines (Drexler and others 1999; Jones and others 1999), and a genetic knockdown of vIL-6 expression using short hairpin RNA (shRNA) or antisense peptide-conjugated oligomers leads to the reduced growth of PEL (Zhang and others 2008; Chen and others 2009b). Conversely, exogenously supplied hIL-6 (or hIL-10) is able to counteract the rapamycin-induced growth arrest in PEL (Sin and others 2007). In other tissue culture models, IL-6 may not be required for the KSHV lifecycle, as a KSHV isolate devoid of vIL-6 showed no implication.
significant difference in establishment, maintenance, and reactivation from latency in transformed B cells (Chen and Lagunoff 2007). We speculate that vIL-6 (and the induction of hIL6) contributes to the initial steps in B-cell transformation toward the hyperplastic KSHV-associated B-cell disease, MCD, and the neoplastic KSHV-associated lymphoma PEL. For MCD, the dependence on IL-6 signaling persists, whereas some PEL eventually develop IL-6 independence. Such a model would be akin to gammaherpesvirus Saimiri-associated T-cell transformation. Here, transformed T-cell clones initially require IL-2 for survival, but over time evolve IL-2 independence.

A homolog of IL-6 was identified in rhesus rhadinovirus (RRV), which is closely related to KSHV. The RRV homolog of IL-6 (RvIL-6) shows 35.6% and 27.4% amino acid sequence similarity to rhesus IL-6 and KSHV vIL-6, respectively. One can expect that the RvIL-6 also adopts the 4-helix bundle fold, although the crystal structure of RvIL-6 has not been solved. The RvIL-6 supports B-cell growth, and antibodies against RvIL-6 neutralize the proliferating activity of the RvIL-6 (Kaleeba and others 1999). RvIL-6 is associated with lymphoproliferative disorder in rhesus macaques (Orzechowska and others 2009). Thus, all IL-6 functions seem to be conserved among primates and primate viruses.

CD is a B-cell lymphoproliferative disorder characterized by lymph node hyperplasia, plasma cell infiltration between the lymphoid follicles, and hypergammaglobulinemia. The main symptoms include fever, anemia, weight loss, and loss of appetite. Elevated expression of host IL-6 has been implicated in disease progression (Yoshizaki and others 1989; Leger-Ravet and others 1991; Mandler and others 1992; Hsu and others 1993). Unicentric CD is localized to a single site, whereas the multicentric form is characterized by lymphadenopathic presentation and systemic symptoms in more than 1 site of the body. The multicentric form of CD is strongly associated with KSHV (Soulier and others 1995). Treatment option for the unicentric form is surgical removal, but there is no standard therapy for the multicentric form. Consistent with the biology of IL-6 blockade of IL-6 signaling by an anti-IL-6R antibody is effective in alleviating MCD symptoms such as fatigue, fever, anemia, hypergammaglobulinemia, and lymphadenopathy (Nishimoto and others 2000; Song and others 2010).

Conclusions
EBV and KSHV are 2 human gammaherpesviruses. They establish long-term latency in B cells and induce hematologic malignancies. In this review, we have discussed functions and activities of EBV’s IL-10 homolog and KSHV’s IL-6 homolog. These viral proteins elicit many of the same phenotypes as their human counterparts and therefore can be thought of as providing functionality in virally infected cell types that do not normally express the corresponding host IL. However, these 2 viral homologs do more than merely filling in for their host counterparts. EBV vIL-10 has lost the immunostimulatory properties of hIL-10. With regard to this phenotype, it represents a hypomorphic variant and potential oncogene. Therapeutic strategies targeting vIL-6 using humanized anticytokine antibodies or soluble decoy receptors could be as effective against PEL and MCD as strategies targeting the hIL-6 (or IL-6R), were it not for the observation that the majority of KSHV vIL-6 does not leave the ER and thus may be more difficult to target.

Acknowledgments
The authors apologize for not citing all the literature on this topic because of space limitations. The authors thank Dr. B. Damania for critical reading and members of the Dittmer and Damania labs for helpful discussions. D.P.D. was supported by funding from the Lymphoma and Leukemia Society (LLS), the National Institutes of Health (NIH), and the University Cancer Research Fund (UCRF).

Author Disclosure Statement
No competing financial interests exist.

References
Breen EC, Gage JR, Guo B, Magpantay L, Narazaki M, Kishimoto T, Miles S, Martínez-Maza O. 2001. Viral interleukin 6 stimulates human peripheral blood B cells that are unre-


Hu F, Nicholas J. 2006. Signal transduction by human herpesvirus 8 viral interleukin-6 (vIL-6) is modulated by the non-signaling gp80 subunit of the IL-6 receptor complex and is distinct from signaling induced by human IL-6. J Virol 80(21):10874–10878.


IARC. 2011. IARC Monographs on the evaluation of carcinogenic risks to humans, Volume 100B. Lyon, France: IARC.


Jones KD, Aoki Y, Chang Y, Moore PS, Yachooan R, Tosato G. 1999. Involvement of interleukin-10 (IL-10) and viral IL-6 in...


Li H, Wang H, Nicholas J. 2001. Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and -independent signaling. J Virol 75(7):3325–3334.


Address correspondence to:
Dr. Dirk P. Dittmer
Department of Microbiology and Immunology and Lineberger Comprehensive Cancer Center
Center for AIDS Research
The University of North Carolina
804 Mary Ellen Jones
CB#7290
Chapel Hill, NC 27599-7290

E-mail: ddittmer@med.unc.edu

Received 27 August 2011/Accepted 6 September 2011